•  11
    Seeing Beyond the Margins: Challenges to Informed Inclusion of Vulnerable Populations in Research
    with Sarah Gehlert
    Journal of Law, Medicine and Ethics 46 (1): 30-43. 2018.
    Although the importance of including vulnerable populations in medical research is widely accepted, identifying how to achieve such inclusion remains a challenge. Ensuring that the language of informed consent is comprehensible to this group is no less of a challenge. Although a variety of interventions show promise for increasing the comprehensibility of informed consent and increasing a climate of exchange, consensus is lacking on which interventions should be used in which situations and curr…Read more
  •  18
    Expanding Our Lens: Thinking Beyond Genomics
    with Shana D. Stites and Dominic A. Sisti
    American Journal of Bioethics 17 (4): 29-31. 2017.
  •  33
    Background: Noninvasive prenatal testing (NIPT) is a new prenatal screening technology that became commercially available in the United States in 2011. NIPT's increased accuracy and low false positive rate compared to previous screening methods enable many women to avoid invasive diagnostic testing and receive much desired reassurance. NIPT has received much attention for both its benefits and drawbacks. Methods: Observation of genetic counseling sessions and qualitative interviews with women of…Read more
  •  17
    Mandating Moral Reflection?
    with Pamela Sankar
    American Journal of Bioethics 17 (1): 32-34. 2017.
  •  23
    Cherchez la Femme: Reproductive CRISPR and Women's Choices
    with Megan Allyse, Marsha Michie, and Rayna Rapp
    American Journal of Bioethics 15 (12): 47-49. 2015.
  •  27
    Toward an Ethically Sensitive Implementation of Noninvasive Prenatal Screening in the Global Context
    with Vardit Ravitsky, Rayna Rapp, Marsha Michie, Subhashini Chandrasekharan, and Megan Allyse
    Hastings Center Report 47 (2): 41-49. 2017.
    Noninvasive prenatal screening using cell-free DNA, which analyzes placental DNA circulating in maternal blood to provide information about fetal chromosomal disorders early in pregnancy and without risk to the fetus, has been hailed as a potential “paradigm shift” in prenatal genetic screening. Commercial provision of cell-free DNA screening has contributed to a rapid expansion of the tests included in the screening panels. The tests can include screening for sex chromosome anomalies, rare subc…Read more